8-K/A
filed October 15, 2025, 7:59 PM ET
ticker NDRA
CIK 0001681682
other material
confidence high
sentiment neutral
materiality 0.75
ENDRA raises $4.9M in private placement to launch digital asset treasury strategy
ENDRA Life Sciences Inc.
- Sold 744,340 shares/pre-funded warrants plus up to 1,488,680 common warrants at $6.57 per unit; $6.81 for director participant.
- Gross proceeds ~$4.9M; up to $14.4M if common warrants exercised; majority allocated to digital asset treasury (DAT) strategy.
- Engaged Arca Investment Management to manage $3.5M of DAT assets; fees 1.25–1.75% AUM + 10–15% performance fee; issued 400,000 advisory warrants.
- Terminated at-the-market equity facility with Ascendiant effective October 13, 2025.
- 2025 annual meeting set for December 9, 2025; record date October 16, 2025; stockholder proposal deadline October 27, 2025.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued 400,000 shares of Common Stock of warrant to Arca Investment Management, LLC.
- Security
- warrant
- Shares
- 400,000 shares of Common Stock
- Purchaser
- Arca Investment Management, LLC
Exact text from the filing
the Company issued to Arca warrants to purchase an aggregate of 400,000 shares of Common Stock (the “Advisory Warrants”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued 744,340 shares of common stock to certain accredited investors for combined purchase price of $6.57.
- Security
- common stock
- Shares
- 744,340 shares
- Purchaser
- certain accredited investors
- Consideration
- combined purchase price of $6.57
Exact text from the filing
at a per share exercise price of $6.32. Each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants were sold at a combined purchase price of $6.57. In accordance with the rules of the Nasdaq Stock Market, a member of the Company’s board of directors who participated in the Offering (the “Director Participant”) purchased
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued 44,660 shares of Common Stock of warrant to Placement Agent for exercise price of $9.47 per share.
- Security
- warrant
- Shares
- 44,660 shares of Common Stock
- Purchaser
- Placement Agent
- Consideration
- exercise price of $9.47 per share
Exact text from the filing
on the Closing Date, the Company issued to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 44,660 shares of Common Stock at an exercise price of $9.47 per share.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued Prefunded Warrants of warrant to certain accredited investors for exercise price of $0.0001 per share.
- Security
- warrant
- Shares
- Prefunded Warrants
- Purchaser
- certain accredited investors
- Consideration
- exercise price of $0.0001 per share
Exact text from the filing
Each of the Prefunded Warrants is exercisable for one share of Common Stock at the exercise price of $0.0001 per share of Common Stock underlying the Prefunded Warrant
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued up to 1,488,680 shares of Common Stock of warrant to certain accredited investors for per share exercise price of $6.32.
- Security
- warrant
- Shares
- up to 1,488,680 shares of Common Stock
- Purchaser
- certain accredited investors
- Consideration
- per share exercise price of $6.32
Exact text from the filing
Each of the Common Warrants is exercisable for one share of Common Stock at the exercise price of $6.32 per share of Common Stock
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.